21 July 2023 : Clinical Research
Ultrasound-Guided Pectoserratus Plane Block and Superficial Serratus Anterior Plane Block for Subcutaneous Implantable Cardioverter-Defibrillator Implantation: A Comparative Study
Marek SzamborskiDOI: 10.12659/MSM.940541
Med Sci Monit 2023; 29:e940541
Table 1 The use of local anesthesia, analgesics, and anesthetics during and after the procedure and adverse events.
| Qualitative variable | n | % | |
|---|---|---|---|
| LA concentration for PECS II | Ropivacaine 0.25% + lidocaine 0.5% | 16 | 100 |
| LA concentration for S-SAP | Ropivacaine 0.25% + lidocaine 0.5% | 6 | 37 |
| Ropivacaine 0.125% + lidocaine 0.25% | 10 | 63 | |
| Additional analgesic dose during the procedure | Ketoprofen 100 mg | 6 | 38 |
| Metamizole 1 g | 1 | 6 | |
| Paracetamol 1 g | 1 | 6 | |
| None | 8 | 50 | |
| Opioid dose during the procedure | Fentanyl 200 μg | 2 | 13 |
| Fentanyl 150 μg | 2 | 13 | |
| Fentanyl 100 μg | 5 | 31 | |
| Fentanyl 75 μg | 1 | 6 | |
| Fentanyl 20 μg | 1 | 6 | |
| None | 5 | 31 | |
| Dose of i.v. anesthetics used during the procedure | Propofol 130 mg | 1 | 6 |
| Propofol 80 mg, ketamine 50 mg | 1 | 6 | |
| Propofol 80 mg | 2 | 14 | |
| Propofol 70 mg, ketamine 50 mg | 1 | 6 | |
| Propofol 60 mg, midazolam 1 mg | 1 | 6 | |
| Propofol 50 mg, ketamine 50 mg | 1 | 6 | |
| Propofol 50 mg, ketamine 30 mg | 1 | 6 | |
| Propofol 50 mg | 1 | 6 | |
| Propofol 40 mg, midazolam 1 mg | 1 | 6 | |
| Propofol 40 mg | 2 | 14 | |
| Propofol 30 mg, ketamine 20 mg | 1 | 6 | |
| Propofol 30 mg | 1 | 6 | |
| Propofol 20 mg, ketamine 20 mg | 1 | 6 | |
| Propofol 10 mg | 1 | 6 | |
| Adverse events during the procedure (no/yes) | No | 13 | 81 |
| Yes | 3 | 19 | |
| Adverse events 24 h after the procedure (no/yes) | No | 14 | 88 |
| Yes | 2 | 12 | |
| Recommendation of the technique by the patient | No opinion | 1 | 6 |
| Yes | 15 | 94 | |
| n – number; LA – local anesthetic; PECS – pectoral nerve blocks II; S-SAP – superficial serratus anterior plane block. | |||






